Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose vs oral iron for tumor-associated iron deficiency anemia
ChiCTR2400089369Phase 4Not yet recruiting
- Sponsor
- Jiangjin Central Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ferric carboxymaltose in cancer-associated anemia (CRA) and iron deficiency anemia (IDA) (2 arms), sponsored by Jiangjin Central Hospital. Primary endpoints: Hemoglobin, Serum ferritin and 1 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
cancer-associated anemia (CRA)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on ChiCTR2400089369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089369.